SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-058627
Filing Date
2023-11-03
Accepted
2023-11-03 12:01:10
Documents
12
Period of Report
2023-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20231101.htm   iXBRL 8-K 50021
  Complete submission text file 0000950170-23-058627.txt   167863

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clsd-20231101_pre.xml EX-101.PRE 9843
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clsd-20231101.xsd EX-101.SCH 2469
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clsd-20231101_lab.xml EX-101.LAB 13360
6 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20231101_htm.xml XML 4717
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 231375133
SIC: 2834 Pharmaceutical Preparations